Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03250299 · ClinicalTrials.gov registry record · Phase 1
Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
A Phase 1 study, sponsored by Basilea Pharmaceutica.
- Terminated
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT03250299 is a Phase 1 study that was terminated before completion, run by Basilea Pharmaceutica. The registered enrollment target is 26 participants.
The verdict
NCT03250299, a Phase 1 study, was terminated before completion, sponsored by Basilea Pharmaceutica.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
This Phase I study investigated the side-effects and best dose of microtubule-targeted agent BAL101553 when given together with radiation therapy in treating patients with newly-diagnosed O6-methylguanine-DNA methyltransferase (MGMT) promoter unmethylated glioblastoma (GBM). Drugs used in chemotherapy, such as microtubule-targeted agent BAL101553, work in different ways to stop the growth of tumor cells, either by killing the cells, stopping them from dividing, or stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving microtubule-targeted agent BAL101553 and radiation therapy may work better in treating patients with GBM.
Interventions
- RADIATION Radiation Therapy
- DRUG Microtubule-Targeted Agent BAL101553
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2017-12-15 |
| Est. Completion | 2022-08-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03250299
The ClinicalTrials.gov registry entry for NCT03250299 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Basilea Pharmaceutica, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Radiation Therapy is the first listed.
NCT03250299 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03250299 about?
NCT03250299 is a clinical study titled "Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma". This Phase I study investigated the side-effects and best dose of microtubule-targeted agent BAL101553 when given together with radiation therapy in treating patients with newly-diagnosed O6-methylguanine-DNA methyltransferase (MGMT) promoter unmethylated glioblastoma (GBM). Drugs used in chemothera...
What is the current status of trial NCT03250299?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2017-12-15. Estimated completion is 2022-08-24.
What interventions are being tested in trial NCT03250299?
The interventions under investigation include: Radiation Therapy (RADIATION), Microtubule-Targeted Agent BAL101553 (DRUG).
Who is sponsoring clinical trial NCT03250299?
This trial is sponsored by Basilea Pharmaceutica, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.